ERBB2 and breast carcinoma: Pertuzumab is approved by FDA to be used as neoadjuvant in combination with trastuzumab (Herceptin®, Hoffmann-La Roche, Basel, Switzerland), another anti-HER2 monoclonal antibody, and docetaxel for the treatment of early stage and metastatic HER2-positive breast cancer [12,13,14].